Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial-Reference-Cited by-同舟云学术

Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial

Published:2020-12 Issue: Volume:111 Page:104928
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Wolf Gregory T.,Liu Siyu,Bellile Emily,Sartor Maureen,Rozek Laura,Thomas Dafydd,Nguyen Ariane^ORCID,Zarins Katie,McHugh Jonathan B.,Moyer Jeff,Patel Mihir,Saba Nabil,Erman Audrey,Martins Wanessa A.,Newman Jason G.,Kaplan Michael,Oliveira Frabicio,Paula Victorina Ana,Bryan Bell R.,Girotto Gustavo C.,Nieva Jorge,Valentino Joseph,Krempl Greg,Cernea Claudio R.,Kraus Dennis,Higgins Kevin,Cruz Felipe J.S.M.,Panwar Aru,Campos Clodoaldo Z.,McCaul Jim

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference60 articles.

1. Pembrolizumab versus methotrexate, docetacel or cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (Keynote-040); a randomized, open-label phase 3 study;Cohen;Lancet,2019

2. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

3. Nivolumab vs. investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression;Ferris;Oral Oncol,2018

4. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up of Keynote-012;Mehra;Br J Cancer,2018

5. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trails in melanoma, lung and genitorurinary cancers;Carbognin;PLoS ONE,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-infiltrating lymphocytes:As a prognostic parameter in oral squamous cell carcinoma;IP Archives of Cytology and Histopathology Research;2024-07-15

2. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;Oral Oncology;2024-07

3. Oral squamous cell carcinomas: state of the field and emerging directions;International Journal of Oral Science;2023-09-22

4. Global research trends in immunotherapy for head and neck neoplasms: A scientometric study;Heliyon;2023-04

5. Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma;Current Opinion in Oncology;2023-03-14